Clinical Trial Update: Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase II trial update for BI 836858 in myelodysplastic syndromes; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• BI 836858

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED | Results posted: 2020-12-21